- Home
- AGEN vs GGT Comparison
AGEN vs GGT Comparison
Compare AGEN & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- GGT
- Stock Information
- Founded
- AGEN 1994
- GGT 1994
- Country
- AGEN United States
- GGT United States
- Employees
- AGEN N/A
- GGT N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GGT Trusts Except Educational Religious and Charitable
- Sector
- AGEN Health Care
- GGT Finance
- Exchange
- AGEN Nasdaq
- GGT Nasdaq
- Market Cap
- AGEN 126.8M
- GGT 144.8M
- IPO Year
- AGEN 2000
- GGT N/A
- Fundamental
- Price
- AGEN $4.29
- GGT $3.99
- Analyst Decision
- AGEN Buy
- GGT
- Analyst Count
- AGEN 2
- GGT 0
- Target Price
- AGEN $14.50
- GGT N/A
- AVG Volume (30 Days)
- AGEN 460.1K
- GGT 59.7K
- Earning Date
- AGEN 11-10-2025
- GGT 01-01-0001
- Dividend Yield
- AGEN N/A
- GGT 15.56%
- EPS Growth
- AGEN N/A
- GGT N/A
- EPS
- AGEN N/A
- GGT 0.83
- Revenue
- AGEN $106,829,000.00
- GGT N/A
- Revenue This Year
- AGEN $60.49
- GGT N/A
- Revenue Next Year
- AGEN N/A
- GGT N/A
- P/E Ratio
- AGEN N/A
- GGT $6.90
- Revenue Growth
- AGEN N/A
- GGT N/A
- 52 Week Low
- AGEN $1.38
- GGT $4.32
- 52 Week High
- AGEN $7.34
- GGT $7.00
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- GGT 41.55
- Support Level
- AGEN $4.17
- GGT $3.87
- Resistance Level
- AGEN $4.60
- GGT $4.20
- Average True Range (ATR)
- AGEN 0.28
- GGT 0.06
- MACD
- AGEN 0.04
- GGT -0.01
- Stochastic Oscillator
- AGEN 61.32
- GGT 30.30
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.